Epizyme, Eisai, Roche Partner to Develop CDx for Investigational Lymphoma Treatment
January 07, 2013
Epizyme, Eisai, Roche Partner to Develop CDx for Investigational Lymphoma Treatment
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Epizyme Taps Roche to Develop Cobas 4800 CDx for Epizyme/Eisai Lymphoma Drug Candidate
January 10, 2013 / PCR Insider - With Celgene Partnership Epizyme Hopes to Accelerate Personalized Epigenetic Drug Development
May 16, 2012 / Pharmacogenomics Reporter - Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 1, 2011 / ProteoMonitor - Roche Unveils Higher-Throughput Cobas Systems as it Maps out MDx Strategy
May 23, 2013 / PCR Insider - Thermo Fisher Contacted Life Tech in 2011 about Possible Acquisition; Document Discloses Other Bidders
May 22, 2013 / GenomeWeb Daily News